NXEN
Nexien BioPharma, Inc.0.0001
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.08KP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Nexien BioPharma posted a Q3 net loss of $30,092 for the quarter ended March 31, 2025, down 43% y/y from $53,163, while nine-month losses narrowed to $101,568 from $152,599. Operating expenses dropped to $14,300 from $15,947 as general and administrative costs fell, yet net losses exceeded operating losses due to $11,429 interest and $4,363 discount amortization on convertible notes. Cash climbed to $8,285 from $4,183 at June 30, 2024, fueled by $55,000 financing inflows topping $50,898 operating outflows; total liabilities hit $458,801 including $70,000 related-party and $207K Quick Capital convertibles at 12%. No revenue yet. Cash stays razor-thin.
10-Q
Q3 FY2025 results
Nexien BioPharma posted a Q3 net loss of $39,472 for the period ended December 31, 2024, up 61% y/y from $24,518, driven by higher professional fees while general and administrative held steady; six-month loss narrowed to $71,476 from $99,436 y/y, excluding 2023's $35,000 stock-based comp to officers. Cash drained to $1,306 from $4,183 at June 30, with operating cash use of $37,877 offset by $35,000 in related-party and convertible note proceeds. Convertible notes to Quick Capital and insiders total ~$277K principal, net of discounts. No revenue, no R&D spend. Cash barely covers bills.
10-Q
Q1 FY2025 results
Nexien BioPharma posted a narrower Q1 FY2025 net loss of $32,004 for the quarter ended September 30, 2024, down 57% y/y from $74,918, yet operating expenses fell to $15,710 from $61,995 on lower stock-based comp. Cash burn eased to $9,230 (derived), offset by $10,000 related-party advance, lifting cash to $4,953 from $4,183 q/q. Convertible notes total $259,898 with $65,000 related-party; stockholders' deficit hit $391,751. Losses stem from interest and note discount amortization. Cash stays razor-thin. Regulatory approval delays loom large.
10-K
FY2024 results
Nexien BioPharma posted FY2024 net loss of $239,113, down 34% y/y from $361,902, yet cash dwindled to $4,183 amid zero revenue and halted R&D for lack of funds. Q4 mirrored the year's stasis—no quarterly breakdowns disclosed, but operating expenses fell to $155,663 on lower stock-based comp to officers ($84,200). Debt swelled with $194,898 Quick Capital notes at 12% and $65,000 related-party convertibles. No dividends, buybacks, or capex. Auditors flag going concern doubt. Substantial doubt shadows continuity.
10-Q
Q3 FY2024 results
Nexien BioPharma posted a Q3 net loss of $53,163 for the quarter ended March 31, 2024, down 33% y/y from $79,853, while nine-month loss narrowed to $152,599 from $268,319. Cash burn eased to $53,480 (derived from cash flow statement), funded by $28,400 in convertible debt proceeds, leaving $10,067 cash against $340K liabilities including $242K to Quick Capital (12% notes due 2024) and $65K related-party notes (18% extended to June 30). No revenue, R&D halted for lack of funds. Officers took 1.25M shares as comp, down from prior year. Cash is nearly gone.
IPO
Sector
Industry
BIOE
Bio Essence Corp.
0.05+0.00
BUDZ
WEED, Inc.
0.06+0.01
CBIH
CANNABIS BIOSCIENCE INTERNATION
0.00-0.00
CPMD
Cannapharmarx Inc.
0.00-0.00
EDXC
ENDEXX Corp.
0.00+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
NIKA
NIKA PHARMACEUTICALS INC.
0.28+0.00
NTRR
Neutra Corp.
0.00+0.00
NXGB
NxGen Brands Inc.
0.00-0.00
VEXTF
Vext Science Inc.
0.22+0.01